You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapse-Refractory Multiple Myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jan 5, 2023

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Nov 17, 2023

Identify Barriers to Cellular Therapies for People With Plasma

Recruiting
  • Multiple Myeloma
  • Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
  • +5 more
  • Basking Ridge, New Jersey
  • +6 more
Nov 6, 2023

Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

Not yet recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Belantamab mafodotin, Venetoclax
  • (no location specified)
May 10, 2023

Learn How Triple Class Refractory Multiple Myeloma Are Treated

Not yet recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
    • (no location specified)
    Feb 15, 2023

    Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

    Recruiting
    • Relapsed and/or Refractory Multiple Myeloma
    • Plasma Cell Leukemia in Relapse
    • Biological
    • Shanghai, Shanghai, China
      Shanghai Tongji Hospital
    May 29, 2023

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Multiple Myeloma in Relapse
    • Autologous CAR-T cell therapy expressing the BAFF-ligand.
    • Cleveland, Ohio
      University Hospitals Seidman Cancer Center
    Jan 11, 2023

    Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

    Recruiting
    • Multiple Myeloma in Relapse
    • Aurora, Colorado
      University of Colorado Hospital
    Jan 31, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • Poitiers, France
      CHU Poitiers
    Jan 9, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Jun 8, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • Anti-GPRC5D CAR-T Cells Injection
    • (no location specified)
    Feb 18, 2023

    Health Technology Intervention on Patient Activation in Multiple

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • +3 more
      • (no location specified)
      Jan 9, 2023

      Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

      Not yet recruiting
      • Multiple Myeloma
      • +4 more
      • Chapel Hill, North Carolina
      • +2 more
      Jun 9, 2023

      Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Aug 8, 2022

      Multiple Myeloma, Relapse Multiple Myeloma Trial in Bethesda, Madison (Descartes-25)

      Recruiting
      • Multiple Myeloma
      • Relapse Multiple Myeloma
      • Shreveport, Louisiana
      • +3 more
      Nov 4, 2022

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

      Recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • Anti-GPRC5D CAR-T cells infusion
      • Kunming, Yunnan, China
      • +1 more
      Feb 21, 2023

      Multiple Myeloma, First Relapse Trial in France (PCD, Autologous transplantation (ASCT))

      Active, not recruiting
      • Multiple Myeloma
      • First Relapse
      • PCD
      • Autologous transplantation (ASCT)
      • Amiens, France
      • +29 more
      Jul 13, 2022

      Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

      Recruiting
      • Relapse Multiple Myeloma
      • Refractory Multiple Myeloma
      • BCMA Targeted CAR T-cells
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital, Medical College, Zhejiang Univers
      Jun 18, 2022

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

      Recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • BCMA CAR-NK
      • +2 more
      • Hangzhou, Zhejiang, China
      • +1 more
      Feb 17, 2023

      Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)

      Recruiting
      • Refractory Multiple Myeloma
      • Relapse Multiple Myeloma
      • Belantamab mafodotin
      • Milwaukee, Wisconsin
        Froedtert & the Medical College of Wisconsin
      Aug 3, 2022

      Relapse/Refractory Multiple Myeloma Trial in China (ATG-010)

      Completed
      • Relapse/Refractory Multiple Myeloma
      • Beijing, Beijing, China
      • +16 more
      Jul 27, 2022

      MMRR Treated With Belantamab Mafotidine on Monotherapy

      Not yet recruiting
      • Multiple Myeloma
      • Belantamab mafodotin
      • (no location specified)
      May 23, 2022

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

      Recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • APRIL CAR-T cells
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital，College of Medicine, Zhejiang Univ
      May 3, 2022